David Goldblatt - Selected Publications#


H Index 45 (198 peer reviewed papers)

1. H.E. Baxendale, Z. Davis, H. N. White, M. B. Spellerberg, F. K. Stevenson, and D. Goldblatt. Immunogenetic analysis of the immune response to pneumococcal polysaccharide. Eur.J Immunol. 30 (4):1214-1223, 2000.
-This paper established that natural exposure to pneumococcus resulted in immune memory, a paradigm that has helped understand adult immunity and vaccine responses

2. Goldblatt D, Hussain M, Andrews N, Ashton L, Virta C, Melegaro A, Pebody R, George R, Soininen A, Edmunds J, Gay N, Kayhty H, Miller Antibody Responses to Nasopharyngeal Carriage of Streptococcus pneumoniae in Adults: A Longitudinal Household Study. J Infect Dis. 2005 192(3):387-93
-Established the mechanism for the finding in Reference 1 (above) showing serum antibody response to pneumococcal capsule after NP carriage

3. McNally LM, Jeena PM, Gajee K, Thula SA, Sturm AW, Cassol S, Tomkins AM, Coovadia HM, Goldblatt D. Impact of Age, Polymicrobial Disease and Maternal HIV Status on Treatment Response and Aetiology of Severe Pneumonia in South African Children. Lancet 2007 369:1440- 1451
-Described the complicated causes for pneumonia in patients with HIV thus informing strategy for first line therapy of pneumonia in HIV endemic areas

4. O'brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis. 2007 7(9):597- 606.
-Gathered the evidence base for the reduced responses following multiple exposures to pneumococcal polysaccharides thus informing vaccine policy for the use of polysaccharide vaccines

5.Hughes SM, Amadi B, Mwiya M, Nkamba H, Tomkins A, Goldblatt D. Dendritic Cell Anergy Results from Endotoxemia in Severe Malnutrition. J Immunol. 2009 183(4):2818-26 PMID 19625445
- Described an immune deficient phenotype in dendritic cells isolated from children with malnutrition in Zambia

6. Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, Pebody R, Miller E. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis. 2009 Nov 1;49 (9):1318-25
-Provided the evidence base for ongoing use of Polysaccharide vaccine in the elderly

7. Goldblatt D, Plikaytis BD, Akkoyunlu M, Antonello J, Ashton L, Blake M, Burton R, Care R, Durant N, Feavers I, Fernsten P, Fievet F, Giardina P, Jansen K, Katz L, Kierstead L, Lee L, Lin J, Maisonneuve J, Nahm M, Raab J, Romero-Steiner S, Rose C, Schmidt D, Stapleton J, Carlone G. Establishment of a new Human Pneumococcal Standard Reference serum 007sp. Clin Vaccine Immunol. 2011 Oct;18(10):1728-36. PMID: 21852547
-I designed and led an international effort to make a new pneumococcal standard reference serum (by immunising 253 volunteers and subsequently collecting blood donations) to
aid standardisation of pneumococcal assays, critical for ongoing vaccine evaluation. WHO have given this material the status of an International Standard and we have stored >15,000 6 ml vials for distribution to laboratories worldwide (will last for at least the next 25 years)

8.Scott JA, Ojal J, Ashton L, Muhoro A, Burbidge P, Goldblatt D. Pneumococcal Conjugate Vaccine Given Shortly After Birth Stimulates Effective Antibody Concentrations and Primes Immunological Memory for Sustained Infant Protection. Clin Infect Dis. 2011 Oct;53(7):663-70. PMID: 21865175
-First description of the use of Pneumococcal Conjugate Vaccine administered within 48 hours of birth. This safe approach is being discussed as part of future WHO policy

9. Chewapreecha C, Harris SR, Croucher NJ, Turner C, Marttinen P, Cheng L, Pessia A, Aanensen DM, Mather AE, Page AJ, Salter SJ, Harris D, Nosten F, Goldblatt D, Corander J, Parkhill J, Turner P, Bentley Dense genomic sampling identifies highways of pneumococcal recombination. Nature Genetics. 2014 Mar;46(3):305-9. PMID: 24509479
-Established the birth cohort study that allowed this insight into mechanisms by which pneumococci share genetic material, only possible as a result of our study design that sampled the nasopharynx of a subset of a 1000 strong birth cohort in Thailand monthly for the first 24 months of life.

10. Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, Slack M, Ladhani SN, Miller E, Goldblatt D. Serotype-specific effectiveness and correlates of protection for 13 valent pneumococcal conjugate vaccine: A post-licensure indirect cohort study. The Lancet Infectious Diseases 18 July 2014 DOI: 10.1016/S1473-3099 PMID:25042756
-This was the first in depth description of the efficacy of the 13 valent pneumococcal conjugate vaccine introduced in the UK in 2010 and, using our unique immunological data set analysed in my laboratory, the first description of serotype specific correlates of protection that will help license new multivalent vaccines

Imprint Privacy policy « This page (revision-4) was last updated on Tuesday, 8. August 2017, 15:44 by System
  • operated by